Navigation Links
MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
Date:9/24/2013

SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of innovative vaccine and antibody based therapies to treat cancer, announces that it has received Contract No. HHSN261201300060C from the National Cancer Institute, National Institutes of Health, under the Small Business Innovation Research Technology Program (SBIR).  The award is in the amount of $1,750,000 over the next three years subject to satisfactory progress and continued availability of funds in the SBIR program.  The grant will support development of a novel positron emission tomography (PET) imaging product for the diagnosis, staging, and treatment assessment of pancreatic cancer.  The product, an antibody fragment linked to a radioactive tracer, is based on the company's discovery of a human antibody designated 5B1 that binds to a cancer antigen expressed on pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC or pancreatic cancer) is a leading cause of cancer-related mortality worldwide primarily due in part to late stage diagnosis stemming from the lack of an early diagnostic screening tool.  It is the fourth most common cause of cancer-related death in the United States with 36,800 deaths reported in 2010.  Five-year relative survival rates have changed very little in the last 40 years.

The carbohydrate antigen sialyl-Lewisa (sLea) is expressed on pancreatic colon and stomach cancers cells at high levels where it is used as a tumor marker and presents an attractive molecular target.  sLea  facilitates tumor adhesion and extravasation that are key events for tumor metastasis, and thus presents a marker for the very cells that cause cancer recurrence.  Increased sLea expression on tumors is correlated with poor clinical outcome.  MabVax Therapeutics has generated fully human monoclonal antibodies against sLea with unusual high affinity for this carbohydrate ligand.  MabVax discovered the 5B1 anti-sLea antibody from a patient who was vaccinated with a sLea anti-cancer vaccine. 

While the intact 5B1 antibody shows promise as a PET imaging agent in an animal model, the use of antibody fragments (5B1 diabodies) is expected to provide additional benefits over intact 5B1.  The 5B1 diabody is expected to show increased clearance from negative tissues and increased tumor retention thereby increasing the signal-to-noise ratio and tumor specificity.  A shorter half-life (i.e. days vs. weeks) also allows clearance of tracers within 1-2 weeks and facilitates unobstructed repeat imaging with the same agent.

There is a clear need for new diagnostic tools that allow earlier detection and for improved therapy regiments.  The radiolabeled 5B1 diabody represents the only human derived agent in development specifically aimed at improving imaging in pancreatic cancer.  Since the antigen targeted by the 5B1 diabody is significantly and preferentially over expressed on metastatic pancreatic cancer, this development effort represents a potentially important step forward in the diagnosis, staging, and assessment of the majority of pancreatic cancer patients.  The company believes that the market opportunity for a 5B1 diabody-based radiopharmaceutical is significant.  The ability of physicians to accurately diagnose, stage, and assess treatment outcomes in pancreatic cancer would be very important.  Additionally, accurate determinations on extent of disease and resectability are essential to improve outcomes in this cancer.  Patients diagnosed with pancreatic cancer could benefit from scans conducting with this new product because of the improvement in the sensitivity and specificity of this key diagnostic tool resulting in a significant impact on clinical outcome.

About MabVax Therapeutics, Inc.
MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer.  MabVax is creating a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company is based in San Diego, CA. MabVax recently closed its third round of Series B venture financing in July of this year. 

Forward Looking Statements

This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements associated with MabVax's expectations regarding the results of this imaging research and the imaging product's potential commercial viability.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as "anticipates," "plans," "expects," "intends," "will," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MabVax's current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):